CereVasc announced an over-subscribed $85 million Series C financing round. The funding was led by Piper Sandler Merchant Banking and included participation from new investors Johnson & Johnson Innovation – JJDC, Inc. and Medtronic, as well as existing investors like Bain Capital Life Sciences and Perceptive Advisors.
This substantial funding round will enable CereVasc to further develop its innovative eShunt System, potentially leading to improved treatment options for patients suffering from normal pressure hydrocephalus and highlighting significant investment interest in neurovascular medical devices.
CereVasc, Inc., a company focused on developing treatments for normal pressure hydrocephalus, has successfully closed an $85 million Series C financing round. The round was significantly over-subscribed, indicating strong investor confidence. Piper Sandler Merchant Banking served as the lead investor. New investors joining the round include Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital arm of Johnson & Johnson, and Medtronic. Existing investors, such as Bain Capital Life Sciences and Perceptive Advisors, also participated, demonstrating continued support for the company's mission. The funds are earmarked to advance CereVasc's novel eShunt® System, designed for the treatment of normal pressure hydrocephalus.
Pick the topics you care about. Get only what matters, on your cadence.